NO971704L - Fremgangsmåte for reversering av multimedikamantsesistens - Google Patents

Fremgangsmåte for reversering av multimedikamantsesistens

Info

Publication number
NO971704L
NO971704L NO971704A NO971704A NO971704L NO 971704 L NO971704 L NO 971704L NO 971704 A NO971704 A NO 971704A NO 971704 A NO971704 A NO 971704A NO 971704 L NO971704 L NO 971704L
Authority
NO
Norway
Prior art keywords
reversing
resistance
multimedia
procedure
dihydronaphthalene
Prior art date
Application number
NO971704A
Other languages
English (en)
Norwegian (no)
Other versions
NO971704D0 (no
Inventor
Srinivasan Chandrasekhar
Anne Hollins Dantzig
Robert Lee Shepard
Ii James Jacob Starling
Mark Alan Winter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO971704D0 publication Critical patent/NO971704D0/no
Publication of NO971704L publication Critical patent/NO971704L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO971704A 1994-10-14 1997-04-14 Fremgangsmåte for reversering av multimedikamantsesistens NO971704L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32317694A 1994-10-14 1994-10-14
PCT/US1995/013036 WO1996011677A1 (en) 1994-10-14 1995-10-13 Methods for treating resistant tumors

Publications (2)

Publication Number Publication Date
NO971704D0 NO971704D0 (no) 1997-04-14
NO971704L true NO971704L (no) 1997-05-13

Family

ID=23258042

Family Applications (1)

Application Number Title Priority Date Filing Date
NO971704A NO971704L (no) 1994-10-14 1997-04-14 Fremgangsmåte for reversering av multimedikamantsesistens

Country Status (14)

Country Link
US (2) US6121292A (hu)
EP (2) EP0820769A3 (hu)
JP (1) JPH10512544A (hu)
CN (1) CN1168631A (hu)
AU (1) AU702301B2 (hu)
CA (1) CA2202661A1 (hu)
CZ (1) CZ113797A3 (hu)
FI (1) FI971568A (hu)
HU (1) HUT77604A (hu)
IL (1) IL115582A0 (hu)
MX (1) MX9702700A (hu)
NO (1) NO971704L (hu)
WO (1) WO1996011677A1 (hu)
ZA (1) ZA958688B (hu)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729754A2 (en) * 1995-02-28 1996-09-04 Eli Lilly And Company 2-Phenyl-3-aroylbonzothiophenes for inhibiting estrogen positive tumors of the brain or CNS
ZA961564B (en) * 1995-02-28 1997-08-27 Lilly Co Eli Methods of inhibiting ovarian cancer.
WO1997017069A1 (en) * 1995-11-07 1997-05-15 Eli Lilly And Company Methods for treating resistant tumors
CA2206752A1 (en) * 1996-07-02 1998-01-02 George Joseph Cullinan Benzothiophene compounds, intermediates, processes, and methods of use
CA2214922A1 (en) * 1996-09-27 1998-03-27 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
BR9713661A (pt) 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
EP0973517A4 (en) 1997-04-30 2002-07-24 Lilly Co Eli ANTITHROMBOTIC AGENTS
AU7470098A (en) 1997-04-30 1998-11-24 Eli Lilly And Company Antithrombotic agents
US6350774B1 (en) 1997-04-30 2002-02-26 Eli Lilly And Company Antithrombotic agents
JP2001522373A (ja) 1997-04-30 2001-11-13 イーライ・リリー・アンド・カンパニー 抗血栓剤
US5840721A (en) * 1997-07-09 1998-11-24 Ontogen Corporation Imidazole derivatives as MDR modulators
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
WO2000019991A1 (en) * 1998-10-02 2000-04-13 Battelle Memorial Institute Inhalation chemotherapy for prevention and treatment of metastatic tumors in the lung
ES2189355T3 (es) * 1998-10-28 2003-07-01 Lilly Co Eli Compuestos de benzotiofeno como agentes antitromboticos e intermedios.
US6558694B2 (en) * 1999-02-19 2003-05-06 Norman A. Brooks Zinc chloride unit dose packaging, applicator, and method of use in treating cancer and other skin diseases
IE20010784A1 (en) * 2000-08-24 2003-04-16 Univ Dublin City N-benzylindole-3-acetic acid derivatives
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US7425565B2 (en) * 2002-05-09 2008-09-16 Cedars-Sinai Medical Center Use of benzothiopenes to treat and prevent prostate cancer
US6630454B2 (en) * 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
AU2003256847A1 (en) * 2002-07-26 2004-02-16 Advanced Research And Technology Institute At Indiana University Method of treating cancer
CN1281210C (zh) * 2003-11-29 2006-10-25 胡汛 五味子乙素在制备治疗肿瘤药物中的应用
BRPI0511834A (pt) * 2004-07-14 2008-01-08 Ptc Therapeutics Inc métodos por tratar hepatite c
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN101022802A (zh) * 2004-07-22 2007-08-22 Ptc医疗公司 用于治疗丙型肝炎的噻吩并吡啶化合物
FR2873692B1 (fr) * 2004-07-29 2006-12-01 Univ Claude Bernard Lyon COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA
FR2913017A1 (fr) * 2007-02-23 2008-08-29 Cerep Sa Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire
CN107108611B (zh) * 2014-12-18 2020-09-25 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN108129375B (zh) * 2018-01-30 2020-04-28 中山大学 化合物及其制备方法与在制备肿瘤耐药逆转剂中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4230862A (en) * 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
CN1108094A (zh) * 1993-10-15 1995-09-13 伊莱利利公司 治疗抗性瘤的方法
EP0736007A4 (en) * 1993-12-21 1997-03-19 Lilly Co Eli NON-PEPTIDE ANTAGONISTS OF TACHYKININ RECEPTORS
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
WO1995017095A1 (en) * 1993-12-21 1995-06-29 Eli Lilly And Company Methods for the treatment or prevention of conditions associated with amyloidogenic reptides

Also Published As

Publication number Publication date
EP0709090A3 (en) 1996-08-28
EP0709090A2 (en) 1996-05-01
CZ113797A3 (en) 1997-09-17
FI971568A0 (fi) 1997-04-14
WO1996011677A1 (en) 1996-04-25
FI971568A (fi) 1997-06-12
US6124311A (en) 2000-09-26
HUT77604A (hu) 1998-06-29
EP0820769A3 (en) 1998-08-19
CN1168631A (zh) 1997-12-24
ZA958688B (en) 1997-04-14
EP0820769A2 (en) 1998-01-28
MX9702700A (es) 1997-06-28
IL115582A0 (en) 1996-01-19
CA2202661A1 (en) 1996-04-25
JPH10512544A (ja) 1998-12-02
US6121292A (en) 2000-09-19
AU702301B2 (en) 1999-02-18
AU3829895A (en) 1996-05-06
NO971704D0 (no) 1997-04-14

Similar Documents

Publication Publication Date Title
NO971704L (no) Fremgangsmåte for reversering av multimedikamantsesistens
AR007609A1 (es) Una composicion farmaceutica
Erl et al. Monocytic cell adhesion to endothelial cells stimulated by oxidized low density lipoprotein is mediated by distinct endothelial ligands
EA199800667A1 (ru) Новые фенантридины
BR0015491A (pt) Métodos para tratar um distúrbio proliferativo celular mediado por ras em um mamìfero, para tratar um neoplasma tendo uma via-ras ativada em um humano, para inibir metástase de um neoplasma tendo uma via-ras ativada em um mamìfero, e para tratar um neoplasma suspeito de ter uma via-ras ativada em um mamìfero, composição farmacêutica, kit, e, método para tratar uma população de células compreendendo um neoplasma suspeito de ter uma via-ras ativada in vitro
ES2176600T3 (es) Derivado de la propiofenona y procedimientos para su preparacion.
EA200000351A1 (ru) Лечение кондуктивных нарушений
ES2154789T3 (es) Procedimiento para la fabricacion de xileno.
ES2174895T3 (es) Combinaciones metalicas complejas con contenido en carbenos heterociclicos.
MX9304360A (es) Derivados de rapamicina y composiciones farmaceuticas de los mismos.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
IT7826837A0 (it) Procedimento per l'unione di cuori di scambi ferroviari, cuori che sono costituiti da acciaio fuso duro al manganese, con rotaie costituite da acciaie al carbonio.
ES540645A0 (es) Aparato para el tratamiento del plasma.
NO990701L (no) Behandling av vanlig forkj°lelse eller allergisk rhinitt
Agnew et al. Isoflurane and coronary heart disease
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
ES2099289T5 (es) Procedimiento para la ciclodimerizacion de 1,3-butadienos a 4-vinilciclohexenos.
EA199800867A1 (ru) Соединения тетрагидробетакарболина
DE69131667D1 (de) Proteinkinase-c-modulatoren mit entzündungshemmender und antiviraler aktivität
CO5160295A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri
NO169386C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 2,3,4,5-tetrahydro-1h-3-benzazepiner
NO832720L (no) Fremgangsmaate for isomerisering av styrenoksyd til fenylaldehyd.
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
DE69327113D1 (de) Methode zum erzeugen von analgie mittels neurotrophine
DE59105500D1 (de) Phenylsulfonamid-substituierte Pyridinalken- und -aminooxyalkancarbonsäure-derivate.